The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Halsey, Christina ^a,b   Docherty, Marie ^a   McNeill, Mhairi ^a   Gilchrist, Derek ^a   Le Brocq, Michelle ^a   Gibson, Brenda ^b   Graham, Gerard ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Acute genetics; Cell differentiation ; Dendritic cells; Down syndrome ; drug effects; GATA1 transcription factor; genetics physiopathology; Humans; Leukaemia; Megakaryoblastic

Indexed keywords

TRANSCRIPTION FACTOR GATA 1;

ARTICLE; CCND2 GENE; CELL DIFFERENTIATION; CELL LINEAGE; CELL STRAIN K 562; ERYTHROID CELL; GATA1FL GENE; GENE EXPRESSION PROFILING; GENE REPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MEGAKARYOCYTE; ONCOGENE MYB; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SKI GENE; TRANSGENE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CONNECTIVE TISSUE GROWTH FACTOR; DNA-BINDING PROTEINS; DOWN SYNDROME; DOWN-REGULATION; ERYTHROID CELLS; GATA1 TRANSCRIPTION FACTOR; HEMATOPOIESIS; HUMANS; K562 CELLS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYB;

EID: 84864413412     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-45     Document Type: Article

References (33)

1. GATA1 function, a paradigm for transcription factors in hematopoiesis. Ferreira R, Ohneda K, Yamamoto M, Philipsen S, Mol Cell Biol 2005 25 1215 1227 10.1128/MCB.25.4.1215-1227.2005 15684376 (Pubitemid 40204902)
2. GATA1 in normal and malignant hematopoiesis. Crispino JD, Semin Cell Dev Biol 2005 16 137 147 10.1016/j.semcdb.2004.11.002 15659348 (Pubitemid 40126884)
3. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down Syndrome. Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD, Blood Cells Mol Dis 2003 31 351 356 10.1016/j.bcmd.2003.08.001 14636651 (Pubitemid 37433876)
4. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down Syndrome. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD, Nat Genet 2002 32 148 152 10.1038/ng955 12172547 (Pubitemid 34977210)
5. Transient leukaemia-a benign form of leukaemia in newborn infants with trisomy 21. Zipursky A, Br J Haematol 2003 120 930 938 10.1046/j.1365-2141.2003. 04229.x 12648061 (Pubitemid 36411551)
6. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Kuhl C, Atzberger A, Iborra F, Nieswandt B, Porcher C, Vyas P, Mol Cell Biol 2005 25 8592 8606 10.1128/MCB.25.19.8592-8606.2005 16166640 (Pubitemid 41369179)
7. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH, Nat Genet 2005 37 613 619 10.1038/ng1566 15895080 (Pubitemid 40770416)
8. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Muntean AG, Crispino JD, Blood 2005 106 1223 1231 10.1182/blood-2005-02-0551 15860665 (Pubitemid 41129583)
9. Transcription factor GATA-1 and Down Syndrome leukemogenesis. Muntean AG, Ge Y, Taub JW, Crispino JD, Leuk Lymphoma 2006 47 986 997 10.1080/ 10428190500485810 16840187 (Pubitemid 44102959)
10. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Hollanda LM, Lima CS, Cunha AF, Albuquerque DM, Vassallo J, Ozelo MC, Joazeiro PP, Saad ST, Costa FF, Nat Genet 2006 38 807 812 10.1038/ng1825 16783379 (Pubitemid 43980602)
11. Perturbed hematopoiesis in the Tc1 mouse model of Down Syndrome. Alford KA, Slender A, Vanes L, Li Z, Fisher EM, Nizetic D, Orkin SH, Roberts I, Tybulewicz VL, Blood 2010 115 2928 2937 10.1182/blood-2009-06-227629 20154221
12. Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Calligaris R, Bottardi S, Cogoi S, Apezteguia I, Santoro C, Proc Natl Acad Sci U S A 1995 92 11598 11602 10.1073/pnas.92.25.11598 8524811 (Pubitemid 26014161)
13. Role of GATA-1s in early hematopoiesis and differences between alternative splicing in human and murine GATA-1. Halsey C, Tunstall O, Gibson B, Roberts I, Graham G, Blood 2010 115 3415 3416 10.1182/blood-2010-02-267930 20413665
14. Abnormalities in the myeloid progenitor compartment in down syndrome fetal liver precede acquisition of GATA1 mutations. Tunstall-Pedoe O, Roy A, Karadimitris A, de la Fuente J, Fisk NM, Bennett P, Norton A, Vyas P, Roberts I, Blood 2008 112 4507 4511 10.1182/blood-2008-04-152967 18689547
15. Gata1 regulates dendritic-cell development and survival. Gutierrez L, Nikolic T, van Dijk TB, Hammad H, Vos N, Willart M, Grosveld F, Philipsen S, Lambrecht BN, Blood 2007 110 1933 1941 10.1182/blood-2006-09-048322 17505015 (Pubitemid 47443907)
16. Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. McKimmie CS, Fraser AR, Hansell C, Gutierrez L, Philipsen S, Connell L, Rot A, Kurowska-Stolarska M, Carreno P, Pruenster M, et al. J Immunol 2008 181 8171 8181 19039854
17. Suppressive effects of transcription factor GATA-1 on cell type-specific gene expression in dendritic cells. Shimokawa N, Nishiyama C, Nakano N, Maeda K, Suzuki R, Hara M, Fukai T, Tokura T, Miyajima H, Nakao A, et al. Immunogenetics 2010 62 421 429 10.1007/s00251-010-0444-1 20405120
18. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. Suzuki N, Suwabe N, Ohneda O, Obara N, Imagawa S, Pan X, Motohashi H, Yamamoto M, Blood 2003 102 3575 3583 10.1182/blood-2003-04-1154 12893747 (Pubitemid 37409373)
19. Induction of erythroid differentiation in the human leukaemia cell line K562. Andersson LC, Jokinen M, Gahmberg CG, Nature 1979 278 364 365 10.1038/278364a0 570644 (Pubitemid 9124381)
20. Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells. Tetteroo PA, Massaro F, Mulder A, Schreuder-van Gelder R, von dem Borne AE, Leuk Res 1984 8 197 206 10.1016/0145-2126(84)90143-7 6232432 (Pubitemid 14149197)
21. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, et al. Proc Natl Acad Sci U S A 2006 103 3339 3344 10.1073/pnas.0511150103 16492768 (Pubitemid 43346471)
22. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down Syndrome megakaryocytic leukemia. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, et al. Blood 2006 107 1570 1581 10.1182/blood-2005-06-2219 16249385 (Pubitemid 43242396)
23. Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Georgopoulos K, Moore DD, Derfler B, Science 1992 258 808 812 10.1126/science.1439790 1439790
24. Molecular and transcriptional regulation of megakaryocyte differentiation. Shivdasani RA, Stem Cells 2001 19 397 407 10.1634/stemcells.19- 5-397 11553848 (Pubitemid 32900082)
25. Proper levels of c-Myb are discretely defined at distinct steps of hematopoietic cell development. Sakamoto H, Dai G, Tsujino K, Hashimoto K, Huang X, Fujimoto T, Mucenski M, Frampton J, Ogawa M, Blood 2006 108 896 903 10.1182/blood-2005-09-3846 16597594 (Pubitemid 44154622)
26. Increased D-type cyclin expression together with decreased cdc2 activity confers megakaryocytic differentiation of a human thrombopoietin-dependent hematopoietic cell line. Matsumura I, Tanaka H, Kawasaki A, Odajima J, Daino H, Hashimoto K, Wakao H, Nakajima K, Kato T, Miyazaki H, Kanakura Y, J Biol Chem 2000 275 5553 5559 10.1074/jbc.275.8.5553 10681535 (Pubitemid 30115191)
27. The ski/sno protooncogene family in hematopoietic development. Pearson-White S, Deacon D, Crittenden R, Brady G, Iscove N, Quesenberry PJ, Blood 1995 86 2146 2155 7662963
28. Ski negatively regulates erythroid differentiation through its interaction with GATA1. Ueki N, Zhang L, Hayman MJ, Mol Cell Biol 2004 24 10118 10125 10.1128/MCB.24.23.10118-10125.2004 15542823 (Pubitemid 39507852)
29. MicroRNA29a regulates the expression of the nuclear oncogene Ski. Teichler S, Illmer T, Roemhild J, Ovcharenko D, Stiewe T, Neubauer A, Blood 2011 118 1899 1902 10.1182/blood-2010-09-306258 21685371
30. Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Ritter M, Kattmann D, Teichler S, Hartmann O, Samuelsson MK, Burchert A, Bach JP, Kim TD, Berwanger B, Thiede C, et al. Leukemia 2006 20 437 443 10.1038/sj.leu.2404093 16424870 (Pubitemid 43291741)
31. Ski is a component of the histone deacetylase complex required for transcriptional repression by mad and thyroid hormone receptor. Nomura T, Khan MM, Kaul SC, Dong HD, Wadhwa R, Colmenares C, Kohno I, Ishii S, Genes Dev 1999 13 412 423 10.1101/gad.13.4.412 10049357 (Pubitemid 29108757)
32. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Quintas-Cardama A, Santos FP, Garcia-Manero G, Leukemia 2011 25 226 235 10.1038/leu.2010.276 21116282
33. Induced differentiation of K562 leukemia cells: a model for studies of gene expression in early megakaryoblasts. Alitalo R, Leuk Res 1990 14 501 514 10.1016/0145-2126(90)90002-Q 2197510 (Pubitemid 20213713)